MedPath

NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome

Not Applicable
Completed
Conditions
Lynch Syndrome
Interventions
Procedure: Colonoscopy
Registration Number
NCT02570516
Lead Sponsor
Assistance Publique - H么pitaux de Paris
Brief Summary

This study compares two colonoscopy techniques (with Narrow Band Imaging versus with indigo carmine chromoendoscopy) in patients having Lynch Syndrome

Detailed Description

Chromoendoscopy using indigo carmine dye is recommended every 1 to 2 years in patients having Lynch Syndrome (LS). However, it is a time-consuming procedure, requiring a prior learning and has an additional cost, the reason why it is not yet systematically practiced in all endoscopy centers. The "Narrow Band Imaging" (NBI) is a recent virtual chromoendoscopy technique using optical filters at the light source of the endoscope to highlight the vascular structures of the mucosa by pressing a button. NBI is currently used to better characterize dysplasia lesions in the esophageal, gastric, and colon mucosa. A new generation (3rd generation) of NBI is currently available on some endoscopes, it can deliver more brightness and contrast, and could allow for better detection of flat lesions. Until today, no study has directly compared colonic chromoendoscopy with Indigo carmine to virtual chromoendoscopy with NBI (3rd generation) in LS patients. The hypothesis that this research aims to verify is that the new generation NBI system might do at least as well as indigo carmine in colonic adenoma detection in LS. This study aims to compare colonoscopy with virtual chromoendoscopy using 3rd generation NBI system to chromoendoscopy with indigo carmine in LS patients, in a back-to-back, prospective non inferiority design, in which all patients will have both techniques in the following order: NBI first followed by Indigo carmine.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
141
Inclusion Criteria
  • Lynch Syndrome with an identified mutation in one of the genes MutL Homolog 1 (MLH1), MutL Homolog 2 (MLH2), MutS homolog6 (MSH6), PMS2 or epithelial cellular adhesion molecule (EpCAM)
  • Age between 18 and 80
  • Indication of a screening colonoscopy
Exclusion Criteria
  • Any sign of intestinal occlusion contra-indicating bowel preparation
  • History of total or subtotal colectomy
  • Any serious medical condition contra-indicating colonoscopy under general anesthesia
  • Pregnant or breast feeding women
  • Any coagulation disorder contra-indicating biopsies or endoscopic resections
  • Any history of hypersensitivity to indigo carmine
  • Adults subject to a legal protection measure (guardianship or curatorship)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Indigo carmine colonoscopyColonoscopyColonoscopy using indigo carmine is performed in second place
NBI colonoscopyColonoscopyColonoscopy using NBI is performed in first place
Primary Outcome Measures
NameTimeMethod
Number of adenomas and / or adenocarcinoma detected during each procedure (NBI vs Indigo carmine)procedure time

The adenoma detection rate (number of adenoma and/or adenocarcinoma) of NBI and the additional adenoma detection rate of indigo carmine.

Secondary Outcome Measures
NameTimeMethod
Number of subject with adverse events as mesure of safety.One month after colonoscopy

Followed a month post colonoscopy to evaluate the occurrence of undesirable events

All neoplastic lesions detected during colonoscopyprocedure time

Collect the number, size, location, endoscopic (Paris Classification) and anatomo-pathologic aspect (adenoma, hyperplastic polyp, adenocarcinoma) of all detected lesions with their respective prevalence.

Duration of each procedure (NBI vs Indigo carmine)Procedure time

Evaluate the duration of each procedure (with and without endoscopic therapy).

Cost of each procedure (NBI vs Indigo carmine)Procedure time

Evaluate the cost of each procedure including therapy.

Trial Locations

Locations (7)

Institut Gustave-Roussy

馃嚝馃嚪

Villejuif, 脦le-de-France, France

AP-HP - H么pital Saint-Antoine

馃嚝馃嚪

Paris, 脦le-de-France, France

CHU Nantes - H么tel-Dieu

馃嚝馃嚪

Nantes, Pays De La Loire, France

CHRU de Tours - H么pital Trousseau

馃嚝馃嚪

Chambray-l猫s-Tours, Centre-Val De Loire, France

AP-HP - H么pital Europ茅en Georges-Pompidou

馃嚝馃嚪

Paris, France

HCL - H么pital Edouard-Herriot

馃嚝馃嚪

Lyon, Auvergne-Rh么ne-Alpes, France

AP-HP - H么pital Cochin

馃嚝馃嚪

Paris, 脦le-de-France, France

漏 Copyright 2025. All Rights Reserved by MedPath